Your browser doesn't support javascript.
loading
Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes.
Rinaldi, Berardo; Bayat, Allan; Zachariassen, Linda G; Sun, Jia-Hui; Ge, Yu-Han; Zhao, Dan; Bonde, Kristine; Madsen, Laura H; Awad, Ilham Abdimunim Ali; Bagiran, Duygu; Sbeih, Amal; Shah, Syeda Maidah; El-Sayed, Shaymaa; Lyngby, Signe M; Pedersen, Miriam G; Stenum-Berg, Charlotte; Walker, Louise Claudia; Krey, Ilona; Delahaye-Duriez, Andrée; Emrick, Lisa T; Sully, Krystal; Murali, Chaya N; Burrage, Lindsay C; Plaud Gonzalez, Julie Ana; Parnes, Mered; Friedman, Jennifer; Isidor, Bertrand; Lefranc, Jérémie; Redon, Sylvia; Heron, Delphine; Mignot, Cyril; Keren, Boris; Fradin, Mélanie; Dubourg, Christele; Mercier, Sandra; Besnard, Thomas; Cogne, Benjamin; Deb, Wallid; Rivier, Clotilde; Milani, Donatella; Bedeschi, Maria Francesca; Di Napoli, Claudia; Grilli, Federico; Marchisio, Paola; Koudijs, Suzanna; Veenma, Danielle; Argilli, Emanuela; Lynch, Sally Ann; Au, Ping Yee Billie; Ayala Valenzuela, Fernando Eduardo.
Afiliación
  • Rinaldi B; Medical Genetics Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy.
  • Bayat A; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Zachariassen LG; Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Dianalund, 4293, Denmark.
  • Sun JH; Department of Regional Health Research, University of Southern Denmark, Odense, 5230  Denmark.
  • Ge YH; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Zhao D; 5State Key Laboratory of Pharmaceutical Biotechnology, Model Animal Research Center, Department of Neurology, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, 210032, China.
  • Bonde K; Zhejiang Key Laboratory of Organ Development and Regeneration, College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou, 310030, China.
  • Madsen LH; 5State Key Laboratory of Pharmaceutical Biotechnology, Model Animal Research Center, Department of Neurology, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, 210032, China.
  • Awad IAA; Ministry of Education Key Laboratory of Model Animal for Disease Study, National Resource Center for Mutant Mice, Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, 210032, China.
  • Bagiran D; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Sbeih A; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Shah SM; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • El-Sayed S; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Lyngby SM; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Pedersen MG; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Stenum-Berg C; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Walker LC; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Krey I; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Delahaye-Duriez A; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Emrick LT; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 2100, Denmark.
  • Sully K; 8Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, K1H 8M5, Canada.
  • Murali CN; Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, 04103, Germany.
  • Burrage LC; Unité fonctionnelle de médecine génomique et génétique clinique, Hôpital Jean Verdier, Assistance Publique des Hôpitaux de Paris, Bondy, 93140, France.
  • Plaud Gonzalez JA; NeuroDiderot, UMR 1141, Inserm, Université Paris Cité, Paris, 75019, France.
  • Parnes M; UFR SMBH, Université Sorbonne Paris Nord, Bobigny, 93000, France.
  • Friedman J; Division of Neurology and Developmental Neurosciences, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, 77030, USA.
  • Isidor B; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, 77030, USA.
  • Lefranc J; Division of Neurology and Developmental Neurosciences, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, 77030, USA.
  • Redon S; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, 77030, USA.
  • Heron D; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, 77030, USA.
  • Mignot C; Division of Neurology and Developmental Neurosciences, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, 77030, USA.
  • Keren B; Division of Neurology and Developmental Neurosciences, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, 77030, USA.
  • Fradin M; Pediatric Movement Disorders Clinic, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas, 77030, USA.
  • Dubourg C; Rady Children's Institute for Genomic Medicine, San Diego, California, 92123, USA.
  • Mercier S; Department of Neurosciences, University of California San Diego, San Diego, CA 92123, USA.
  • Besnard T; Department of Pediatrics, University of California San Diego, San Diego, CA 92123, USA.
  • Cogne B; Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, 44000, France.
  • Deb W; Pediatric Neurophysiology Department, CHU de Brest, Brest, 29200, France.
  • Rivier C; Service de Génétique Médicale, CHU de Brest, Brest, 29200, France.
  • Milani D; University of Brest, Inserm, EFS, UMR 1078, GGB, Brest, 29200, France.
  • Bedeschi MF; APHP Sorbonne Université, Département de Génétique, Hôpital Armand Trousseau and Groupe Hospitalier Pitié-Salpêtrière, Paris, 75013, France.
  • Di Napoli C; Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, 75013, France.
  • Grilli F; APHP Sorbonne Université, Département de Génétique, Hôpital Armand Trousseau and Groupe Hospitalier Pitié-Salpêtrière, Paris, 75013, France.
  • Marchisio P; Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, 75013, France.
  • Koudijs S; Genetic Department, APHP, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, 75013, France.
  • Veenma D; Service de Génétique Médicale, Hôpital Sud, CHU de Rennes, Rennes, 35200, France.
  • Argilli E; Service de Génétique Moléculaire et Génomique, CHU de Rennes, Rennes, 35200, France.
  • Lynch SA; Université de Rennes, CNRS, Institut de Genetique et Developpement de Rennes, UMR 6290, Rennes, 35200, France.
  • Au PYB; Nantes Université, CHU Nantes, Service de Génétique Médicale, Nantes, 44000, France.
  • Ayala Valenzuela FE; Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, 44000, France.
Brain ; 2023 Dec 01.
Article en En | MEDLINE | ID: mdl-38038360
ABSTRACT
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors (AMPARs) mediate fast excitatory neurotransmission in the brain. AMPARs form by homo- or heteromeric assembly of subunits encoded by the GRIA1-GRIA4 genes, of which only GRIA3 is X-chromosomal. Increasing numbers of GRIA3 missense variants are reported in patients with neurodevelopmental disorders (NDD), but only a few have been examined functionally. Here, we evaluated the impact on AMPAR function of one frameshift and 43 rare missense GRIA3 variants identified in patients with NDD by electrophysiological assays. Thirty-one variants alter receptor function and show loss-of-function (LoF) or gain-of-function (GoF) properties, whereas 13 appeared neutral. We collected detailed clinical data from 25 patients (from 23 families) harbouring 17 of these variants. All patients had global developmental impairment, mostly moderate (9/25) or severe (12/25). Twelve patients had seizures, including focal motor (6/12), unknown onset motor (4/12), focal impaired awareness (1/12), (atypical) absence (2/12), myoclonic (5/12), and generalized tonic-clonic (1/12) or atonic (1/12) seizures. The epilepsy syndrome was classified as developmental and epileptic encephalopathy in eight patients, developmental encephalopathy without seizures in 13 patients, and intellectual disability with epilepsy in four patients. Limb muscular hypotonia was reported in 13/25, and hypertonia in 10/25. Movement disorders were reported in 14/25, with hyperekplexia or non-epileptic erratic myoclonus being the most prevalent feature (8/25). Correlating receptor functional phenotype with clinical features revealed clinical features for GRIA3-associated NDDs and distinct NDD phenotypes for LoF and GoF variants. GoF variants were associated with more severe

outcomes:

patients were younger at the time of seizure onset (median age one month), hypertonic, and more often had movement disorders, including hyperekplexia. Patients with LoF variants were older at the time of seizure onset (median age 16 months), hypotonic, and had sleeping disturbances. LoF and GoF variants were disease-causing in both sexes but affected males often carried de novo or hemizygous LoF variants inherited from healthy mothers, whereas all but one affected females had de novo heterozygous GoF variants.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Brain Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Brain Año: 2023 Tipo del documento: Article País de afiliación: Italia